Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

InMed Pharmaceuticals (INM) EBIT (2021 - 2025)

InMed Pharmaceuticals' EBIT history spans 5 years, with the latest figure at -$2.1 million for Q4 2025.

  • For Q4 2025, EBIT rose 6.72% year-over-year to -$2.1 million; the TTM value through Dec 2025 reached -$7.9 million, changed 0.17%, while the annual FY2025 figure was -$7.9 million, 3.05% up from the prior year.
  • EBIT reached -$2.1 million in Q4 2025 per INM's latest filing, down from -$1.8 million in the prior quarter.
  • In the past five years, EBIT ranged from a high of -$485150.0 in Q2 2023 to a low of -$6.5 million in Q2 2022.
  • Average EBIT over 5 years is -$2.5 million, with a median of -$2.1 million recorded in 2023.
  • Peak YoY movement for EBIT: skyrocketed 92.56% in 2023, then crashed 319.3% in 2024.
  • A 5-year view of EBIT shows it stood at -$4.3 million in 2021, then skyrocketed by 48.66% to -$2.2 million in 2022, then grew by 25.7% to -$1.6 million in 2023, then tumbled by 37.03% to -$2.3 million in 2024, then rose by 6.72% to -$2.1 million in 2025.
  • Per Business Quant, the three most recent readings for INM's EBIT are -$2.1 million (Q4 2025), -$1.8 million (Q3 2025), and -$1.8 million (Q2 2025).